Log in

NASDAQ:MCURMacrocure Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 01/31/2017)
Today's Range
Now: $1.51
50-Day Range N/A
52-Week Range
Now: $1.51
Average Volume98,746 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.
Read More
Macrocure logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:MCUR



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive MCUR News and Ratings via Email

Sign-up to receive the latest news and ratings for MCUR and its competitors with MarketBeat's FREE daily newsletter.

Macrocure (NASDAQ:MCUR) Frequently Asked Questions

How were Macrocure's earnings last quarter?

Macrocure Ltd (NASDAQ:MCUR) released its earnings results on Tuesday, November, 17th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.04. View Macrocure's earnings history.

Has Macrocure been receiving favorable news coverage?

Media stories about MCUR stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Macrocure earned a coverage optimism score of -4.8 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutMacrocure.

What other stocks do shareholders of Macrocure own?

What is Macrocure's stock symbol?

Macrocure trades on the NASDAQ under the ticker symbol "MCUR."

What is Macrocure's stock price today?

One share of MCUR stock can currently be purchased for approximately $1.51.

What is Macrocure's official website?

The official website for Macrocure is www.macrocure.com.

How can I contact Macrocure?

Macrocure's mailing address is 25 Sivim Street, PETAH TIKVA, 4959383, Israel. The biotechnology company can be reached via phone at +972-3-9235556.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.